SAB Biotherapeutics (SABS) Common Equity (2020 - 2026)
SAB Biotherapeutics' (SABS) quarterly Common Equity came in at $227.2 million in Q1 2026, up 961.54% YoY from $21.4 million in Q1 2025, and up 50.0% on a QoQ basis from $151.5 million in Q4 2025.
SAB Biotherapeutics (SABS) Common Equity (2020 - 2026) Analysis & Trends
SAB Biotherapeutics (SABS) has 7 years of Common Equity data on file, last reported at $227.2 million in Q1 2026.
- Quarterly Common Equity rose 961.54% year-over-year to $227.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $227.2 million (up 961.54% YoY) and the FY2025 annual result came in at $151.5 million, up 483.35% from the prior year.
- Common Equity grew to $227.2 million in Q1 2026, from $151.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $227.2 million in Q1 2026 to a low of $12.0 million in Q2 2025.
- A 5-year average of $58.6 million and a median of $36.9 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2025 — Common Equity sank 73.95% — and 2026, when it surged 961.54%.
- Tracing SABS's Common Equity over 5 years: stood at $31.1 million in 2022, then jumped by 84.49% to $57.3 million in 2023, then sank by 54.68% to $26.0 million in 2024, then surged by 483.35% to $151.5 million in 2025, then surged by 50.0% to $227.2 million in 2026.
- The last three Common Equity figures came in at $227.2 million (Q1 2026), $151.5 million (Q4 2025), and $165.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | SAB Biotherapeutics | 308.92 Mn | 308.92 Mn | - | 214.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 214.79 Mn |
| Mar 31, 2026 | 227.25 Mn |
| Dec 31, 2025 | 151.49 Mn |
| Sep 30, 2025 | 165.07 Mn |
| Jun 30, 2025 | 12.02 Mn |
| Mar 31, 2025 | 21.41 Mn |
| Dec 31, 2024 | 25.97 Mn |
| Sep 30, 2024 | 36.90 Mn |
| Jun 30, 2024 | 46.12 Mn |
| Mar 31, 2024 | 52.82 Mn |
| Dec 31, 2023 | 57.30 Mn |
| Sep 30, 2023 | 15.26 Mn |
| Jun 30, 2023 | 19.72 Mn |
| Mar 31, 2023 | 24.40 Mn |
| Dec 31, 2022 | 31.06 Mn |
| Sep 30, 2022 | 30.62 Mn |
| Jun 30, 2022 | 37.12 Mn |
| Mar 31, 2022 | 41.26 Mn |
| Dec 31, 2021 | 38.55 Mn |
| Sep 30, 2021 | 35.08 Mn |